SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty b...
21 6월 2013 - 1:06AM
Business Wire
Levi & Korsinsky is investigating potential claims on behalf
of purchasers of Vanda Pharmaceuticals, Inc. (“Vanda” or the
“Company”) (NasdaqGM: VNDA) stock. The investigation stems from
concerns regarding the Company’s Phase III trials for the drug
Tasimelteon.
For more information, click here:
http://zlk.9nl.com/vanda-pharmaceuticals-vnda/.
On May 31, 2013, Vanda submitted a New Drug Application (“NDA”)
for Tasimelteon to the U.S. Food and Drug Administration. Then on
June 19, 2013, an article was published on thestreet.com,
questioning the efficacy of Vanda’s study, noting that the study
not only changed multiple times, but that it replaced the primary
endpoint just a month before study results were announced; this
replacement primary endpoint was not endorsed by the FDA and had
never been used in clinical trials for this type of medication. On
the news, shares of Vanda closed at $8.51 per share on June 19,
2013, a drop of more than 20% from the previous day.
If you own Vanda stock and wish to obtain additional information
about the investigation and your legal rights, please contact
Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by
telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit
http://zlk.9nl.com/vanda-pharmaceuticals-vnda/.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, and Washington D.C. The firm has extensive
expertise in prosecuting securities litigation involving financial
fraud, representing investors throughout the nation in securities
and shareholder lawsuits. The attorneys at Levi & Korsinsky
have been appointed by numerous courts throughout the country to
serve as lead counsel on behalf of shareholders in major securities
lawsuits and have successfully recovered multimillion-dollar
damages awards on behalf of investors. For more information, please
feel free to contact any of the attorneys listed below. Attorney
advertising. Prior results do not guarantee similar outcomes.
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024